In common with most infectious agents, meningococci invade mucosal membranes before causing disease (1). An attractive vaccine strategy is therefore to induce immunological responses at the mucosal surfaces, with the possibility of blocking microbial invasion, as well as to induce systemic immunity with the capacity of inactivating the microbes.